Colistimethate Sodium Efficacy and Safety in Carbapenem-Resistant Infections, 2021-2023

Between November 2021 and November 2023, a prospective observational study in nine ICUs in Henan Province, China, enrolled 222 patients aged 14 or older with culture-confirmed carbapenem-resistant Gram-negative bacilli (CR-GNB) infections. The dataset, authored by Tingyuan Zhang, records clinical and microbiological response rates, 30-day all-cause mortality, and safety outcomes including acute kidney injury incidence for patients receiving colistimethate sodium treatment.

Use Cases

• Modeling risk factors for poor clinical response based on APACHE II scores, infection site, and microbial profile.
• Analyzing the incidence and severity of acute kidney injury associated with colistimethate sodium treatment.
• Comparing clinical efficacy outcomes between patients with single-site versus multi-site CR-GNB infections.
• Investigating mortality predictors in ICU patients with polymicrobial versus monomicrobial resistant infections.

Strengths

• Data is from a prospective, observational study design, which likely provides structured clinical records.
• Study includes 222 consecutively enrolled patients from nine ICUs, providing a specific cohort size.
• Reports specific outcome metrics, including an 82.5% clinical response rate and a 20.4% incidence of acute kidney injury.

Limitations

• Row count and column-level documentation are unknown, which limits suitability assessment for specific analytical tasks.
• Data is contained in a 12.7 KB DOCX file, suggesting a very limited scope, likely a summary table rather than a full patient-level dataset.
• Geographic coverage is limited to nine ICUs in Henan Province, China, which may affect generalizability.

Provenance

Source

Tingyuan Zhang via figshare.

Collection Method

Prospective observational study in nine ICUs.

Time Range

November 2021 to November 2023.

Freshness

Last updated 2026-05-29 04:45:27; freshness should be verified.

Geography

Henan Province, China.